McAdam LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

McAdam LLC’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-17	Closed	-$2K	–	690
2018 Q3	$2K	Hold	17	–	–	﹤0.01%	548
2018 Q2	$2K	Sell	17 -17	-50%	-$1.99K	﹤0.01%	520
2018 Q1	$4K	Buy	+34	New	+$4.06K	﹤0.01%	449

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

McAdam LLC's ALXN Position: Q4 2018 in Review

McAdam LLC sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 17 shares — an estimated $2K sold.

McAdam LLC first reported a position in ALXN in Q1 2018 and held it in 3 quarters. The position peaked at $4K in Q1 2018. 609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

McAdam LLC reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 17 Alexion Pharmaceuticals shares in Q4 2018, an estimated $2K.
McAdam LLC first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 3 quarters.
McAdam LLC's Alexion Pharmaceuticals position peaked at $4K in Q1 2018.
609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.